CriticalHIV protease inhibitor / pharmacokinetic booster×Highly selective α1A-adrenergic blocker
Updated · Methodology
Mechanism
The liver clears silodosin mainly through the enzymes CYP3A4, alcohol dehydrogenase and UGT2B7, and P-glycoprotein (P-gp) transports it. Substances that inhibit these enzymes and transporters, ritonavir among them, can change the levels of silodosin and its active metabolite (silodosin summary of product characteristics, SmPC, European Medicines Agency, EMA). Ritonavir strongly inhibits CYP3A and can inhibit P-gp (ritonavir SmPC, EMA). In an interaction study, ketoconazole 400 mg, another strong CYP3A4 inhibitor, raised peak silodosin concentration 3.7-fold and the area under the curve (AUC) 3.1-fold (silodosin SmPC, EMA). According to the US silodosin label, ritonavir may also raise silodosin levels (silodosin label, US Food and Drug Administration, FDA). A QT study gave silodosin 24 mg to reproduce worst-case exposure, such as with strong CYP3A4 inhibitors. This dose did not prolong the corrected QT interval (silodosin FDA label).
Symptoms
The main risk of the pair is postural hypotension, which is why silodosin is contraindicated with nirmatrelvir/ritonavir (nirmatrelvir/ritonavir summary of product characteristics, SmPC, European Medicines Agency, EMA). Postural hypotension shows as dizziness on standing and, rarely, fainting (silodosin SmPC, EMA). It was the dose-limiting reaction in healthy men who took up to 48 mg of silodosin a day (silodosin SmPC, EMA). The most common adverse effects of silodosin are ejaculation disorders: retrograde ejaculation and reduced or absent ejaculate (silodosin SmPC, EMA).
Management
The US silodosin label contraindicates the combination. It names ritonavir among the strong CYP3A4 inhibitors that silodosin must not be taken with, with no condition on the ritonavir dose (silodosin label, US Food and Drug Administration, FDA). Silodosin is contraindicated in both Europe and the US with the 5-day COVID-19 course of nirmatrelvir plus ritonavir 100 mg every 12 hours (nirmatrelvir/ritonavir summary of product characteristics, SmPC, European Medicines Agency, EMA; nirmatrelvir/ritonavir FDA label). The European silodosin SmPC is softer but also advises against the pair: it does not recommend silodosin with strong CYP3A4 inhibitors and names ritonavir among them (silodosin SmPC, EMA). The ritonavir documents do not name silodosin. Among alpha-blockers, they contraindicate only alfuzosin, because of the risk of severe hypotension (ritonavir SmPC, EMA, and FDA label). Before and during ritonavir treatment, review all concomitant medicines. When ritonavir boosts another protease inhibitor, also read the prescribing information of that drug (ritonavir SmPC, EMA, and FDA label). At the first signs of postural hypotension, such as dizziness on standing, ask the patient to sit or lie down until the symptoms pass (silodosin SmPC, EMA). When starting silodosin, warn the patient about driving and operating machinery (silodosin FDA label). If an overdose of silodosin causes hypotension, provide cardiovascular support. Dialysis is unlikely to help because silodosin is highly protein-bound (silodosin SmPC, EMA).
Your whole list in one report
Up to 15 drugs: every pair in one table and a PDF report. Your first report is free: we only ask for your email
Add more drugsMedicine list: everything you take in one place →
Sources
- FDA: Norvir (ritonavir) prescribing information (2026)– AbbVie. NORVIR (ritonavir) tablets, oral solution, oral powder. Prescribing information, DailyMed setid 2849298e-de6e-47bb-8194-56e075b33fc3, sections 4 and 7.2
- EMA: Ficha técnica: Ritonavir (EU/1/96/016), sección 4.3 (2026)– EMA, Norvir, ficha técnica en CIMA (nº registro 96016005), consultada 03.10.2026, secciones 4.3, 4.4 y 4.5
- EMA: Ficha técnica: Nirmatrelvir/ritonavir (EU/1/22/1625), sección 4.3 (2026)– EMA, Paxlovid, ficha técnica en CIMA (nº registro 1221625001), consultada 03.10.2026, secciones 4.3 y 4.5
- FDA: PAXLOVID (nirmatrelvir; ritonavir) prescribing information (2026)– FDA, DailyMed setid 8a99d6d6-fd9e-45bb-b1bf-48c7f761232a, revisión 02/2026 (versión 12), secciones 4 y 7.3
- FDA: Silodosin capsules (silodosin) prescribing information (2026)– FDA, DailyMed setid ee8d577e-948d-4164-9671-c876544ac83b (Novadoz Pharmaceuticals, MSN Laboratories), versión 3, revisión 06/2026, secciones 4, 5.1, 5.4, 7.1 y 12.2; la sección 4 coincide con la de RAPAFLO (setid 96425d91-cfe1-477d-a130-b58c330ca8a3, 02/2012)
- EMA: Ficha técnica: Silodosina – Urorec (EU/1/09/608), sección 4.5 (2026)– EMA, Urorec 8 mg cápsulas duras (Recordati, autorización europea por procedimiento centralizado), ficha técnica en CIMA, nº registro 09608011, consultada 16.10.2026, sin fecha de revisión en CIMA, secciones 4.4, 4.5, 4.8 y 4.9